Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 43.75 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 18.64 | Oscillator | Buy |
| Williams %R (14) | -77.01 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.22 (Hist -0.18) | Oscillator | Strong Sell |
| Average Directional Index (14) | 18.36 (+DI 15.8 / -DI 24.9) | Trend | Neutral |
Current price $20.10
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 4, 26 | Piper Sandler |
| EMA 20 | 20.71 | MA | Sell |
| SMA 20 | 21.04 | MA | Strong Sell |
| EMA 50 | 20.54 | MA | Sell |
| SMA 50 | 20.58 | MA | Sell |
| SMA 200 | 19.55 | MA | Buy |
| maintain |
| Neutral |
| Neutral |
| May 5, 26 | Piper Sandler | maintain | Neutral | Neutral |
| Nov 11, 25 | Piper Sandler | maintain | Neutral | Neutral |
| Aug 5, 25 | UBS | upgrade | Neutral | Buy |
| Aug 4, 25 | Piper Sandler | maintain | Neutral | Neutral |
| May 6, 25 | Piper Sandler | maintain | Neutral | Neutral |
| May 5, 25 | Raymond James | maintain | Outperform | Outperform |
| Mar 4, 25 | Piper Sandler | maintain | Neutral | Neutral |
| Nov 11, 24 | Piper Sandler | maintain | Neutral | Neutral |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 1, 26 | Kim Paul | officer: CFO and Treasurer | F-InKind | 2,087 @ $19.59 | $40.88K |
| Sep 1, 26 | Hsieh Ming | director, 10 percent owner, officer: Chief Executive Officer | F-InKind | 4,392 @ $19.59 | $86.04K |
| Sep 2, 26 | Gao Hanlin | officer: Chief Scientific Officer | S-Sale | 1,673 @ $19.66 | $32.89K |
| Sep 2, 26 | Xie Jian | officer: President and COO | S-Sale | 2,127 @ $19.66 | $41.81K |
| Aug 26, 26 | Hsieh Ming | director, 10 percent owner, officer: Chief Executive Officer | F-InKind | 2,949 @ $19.81 | $58.42K |
| Aug 26, 26 | Kim Paul | officer: CFO and Treasurer | F-InKind | 1,168 @ $19.81 | $23.14K |
| Aug 27, 26 | Xie Jian | officer: President and COO | S-Sale | 1,193 @ $19.91 | $23.75K |
| Aug 27, 26 | Gao Hanlin | officer: Chief Scientific Officer | S-Sale | 939 @ $19.91 | $18.69K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 4 | Sep 3, 2026 | 2026-09-03 19:48:21 | View |
| 4 | Sep 3, 2026 | 2026-09-03 19:47:47 | View |
| 4 | Sep 3, 2026 | 2026-09-03 19:47:39 | View |
| 4 | Sep 3, 2026 | 2026-09-03 19:47:30 | View |
| 144 | Sep 2, 2026 | 2026-09-02 20:42:33 | View |
| 144 | Sep 2, 2026 | 2026-09-02 20:42:17 | View |
| 4 | Aug 28, 2026 | 2026-08-28 18:06:48 | View |
| 4 | Aug 28, 2026 | 2026-08-28 18:06:23 | View |
| 4 | Aug 28, 2026 | 2026-08-28 18:06:00 | View |
| 4 | Aug 28, 2026 | 2026-08-28 18:05:20 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | FLGT | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -7.1x | -3.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -8.9x | EPS est. -2.27 | Elevated |
| Price / Book | 0.6x | 1.0x | Discount |
| Price / Sales | 1.7x | 2.4x | Discount |
| EV / EBITDA | -8.2x | -6.6x | Elevated |
| Return on equity | -7.9% | — | Weak |
| Gross margin | 35.6% | 50.4% | Below hist. |
| Debt / Equity | 0.01 | 0.02 | Conservative |
| Piotroski / Altman Z | 5/9 | Z 4.61 | Safe zone |
Discounted cash flow model
Stock news · updated daily
Fulgent Genetics (NASDAQ: FLGT - Get Free Report) and Agilon Health (NYSE: AGL - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk and profitability. Valuation and Earnings This table compares Fulgent
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its third quarter 2026 financial results after the market closes on Thursday, November 5, 2026. Management will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer q.
Corient Private Wealth LP cut its stake in Fulgent Genetics, Inc. (NASDAQ: FLGT) by 34.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,394 shares of the company's stock after selling 24,261 shares during the period. Corient Private Wealth
Precipio and Fulgent Genetics differ in business scope, valuation and growth drivers, but which cancer diagnostics stock looks more compelling now? Let's dive in.
Hsbc Holdings PLC purchased a new stake in shares of Fulgent Genetics, Inc. (NASDAQ: FLGT) in the second quarter, according to the company in its most recent filing with the SEC. The fund purchased 45,048 shares of the company's stock, valued at approximately $915,000. Hsbc Holdings PLC owned about 0.16% of Fulgent Genetics
Fulgent Genetics, Inc. (FLGT) Q2 2026 Earnings Call Transcript
Fulgent Genetics NASDAQ: FLGT reported second-quarter 2026 revenue of $85.4 million, up 20% sequentially and 4% from a year earlier, as the company incorporated a full quarter of contributions from Bako Diagnostics and StrataDx. Management also lowered its full-year revenue outlook, citing lower collection rates during a transition to a new billing and revenue-cycle-management system.
Fulgent Genetics, Inc. (FLGT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to earnings of $0.07 per share a year ago.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 30, 2026 | -0.46 | -0.58 | Miss -26.1% | $85.39M |
| May 1, 2026 | -0.35 | -0.36 | Miss -3.4% | $71.14M |
| Feb 27, 2026 | 0.03 | 0.16 | Beat 433.3% | $83.34M |
| Nov 7, 2025 | -0.24 | 0.14 | Beat 158.3% | $84.07M |
| Aug 1, 2025 | -0.23 | 0.07 | Beat 130.4% | $81.80M |
| May 2, 2025 | -0.19 | 0.04 | Beat 121.1% | $73.46M |
